IRIS
MANZELLA, LIVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.343
EU - Europa 1.911
AS - Asia 1.694
SA - Sud America 449
AF - Africa 346
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.213
IT - Italia 779
SG - Singapore 769
CN - Cina 553
BR - Brasile 410
IE - Irlanda 386
UA - Ucraina 251
CI - Costa d'Avorio 230
DE - Germania 132
IN - India 130
CA - Canada 117
RU - Federazione Russa 100
SN - Senegal 68
VN - Vietnam 63
GB - Regno Unito 54
KR - Corea 44
FI - Finlandia 38
SE - Svezia 28
BE - Belgio 24
FR - Francia 17
NL - Olanda 17
PL - Polonia 17
UZ - Uzbekistan 17
HK - Hong Kong 16
AR - Argentina 15
JP - Giappone 15
NG - Nigeria 14
BD - Bangladesh 13
CZ - Repubblica Ceca 13
TR - Turchia 13
MA - Marocco 10
MX - Messico 10
ES - Italia 9
IL - Israele 9
IQ - Iraq 9
AT - Austria 8
CH - Svizzera 8
ID - Indonesia 8
ZA - Sudafrica 8
EC - Ecuador 7
IR - Iran 7
GR - Grecia 6
LB - Libano 6
TN - Tunisia 6
SA - Arabia Saudita 5
CO - Colombia 4
EG - Egitto 4
NO - Norvegia 4
PE - Perù 4
PY - Paraguay 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
BG - Bulgaria 3
RS - Serbia 3
VE - Venezuela 3
AL - Albania 2
DZ - Algeria 2
HU - Ungheria 2
JO - Giordania 2
KE - Kenya 2
LT - Lituania 2
LU - Lussemburgo 2
NI - Nicaragua 2
PK - Pakistan 2
AM - Armenia 1
BH - Bahrain 1
CL - Cile 1
DO - Repubblica Dominicana 1
EU - Europa 1
GA - Gabon 1
KH - Cambogia 1
KZ - Kazakistan 1
LY - Libia 1
NP - Nepal 1
OM - Oman 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.748
Salva come PNG Salva come JPEG
Città #
Santa Clara 760
Dallas 731
Singapore 484
Chandler 459
Dublin 386
Chicago 295
Jacksonville 257
Abidjan 230
Catania 204
Boardman 146
Ashburn 133
Nanjing 107
Cambridge 106
Lawrence 106
Andover 101
Beijing 92
Kochi 89
Hefei 83
Los Angeles 79
Toronto 77
Grafing 69
Dakar 67
Civitanova Marche 58
Wilmington 52
San Mateo 50
Des Moines 49
New York 45
Seoul 43
Palermo 40
Munich 28
Nanchang 28
Bari 25
São Paulo 25
Brussels 24
Portland 24
Seattle 24
The Dalles 24
Milan 23
Columbus 22
Saint Petersburg 22
Shenyang 22
Dong Ket 21
Council Bluffs 19
Hanoi 19
Rome 19
Turku 19
Changsha 18
Hebei 18
Ottawa 18
Belo Horizonte 17
Santa Venerina 17
Jiaxing 15
Messina 15
Tianjin 15
Abuja 14
Bremen 14
Tokyo 14
Aci Catena 13
Brno 13
Hong Kong 13
Montreal 13
Pune 12
Brasília 11
Rio de Janeiro 11
Falls Church 10
Lappeenranta 10
Augusta 9
Helsinki 9
Moscow 9
San Francisco 9
Warsaw 9
Boston 8
Brooklyn 8
Curitiba 8
Ho Chi Minh City 8
Leawood 8
Redmond 8
Cosenza 7
Frankfurt am Main 7
Jakarta 7
Jinan 7
Manchester 7
Mascalucia 7
Modica 7
Norwalk 7
Phoenix 7
Porto Alegre 7
San Giovanni la Punta 7
Tashkent 7
Washington 7
Zhengzhou 7
London 6
Manaus 6
Ningbo 6
Agrigento 5
Chennai 5
Edinburgh 5
Fairfield 5
Giardini-Naxos 5
Guarulhos 5
Totale 6.306
Salva come PNG Salva come JPEG
Nome #
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 185
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 175
Activation of the s100a7/rage pathway by igf-1 contributes to angiogenesis in breast cancer 137
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 128
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 123
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 120
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 119
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 119
Biomarkers and prognostic factors for malignant pleural mesothelioma 112
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 109
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 108
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 108
Combined use of sonographic and elastosonographic parameters can improve the diagnostic accuracy in thyroid nodules at risk of malignancy at cytological examination 105
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 105
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 104
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 102
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 101
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 101
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 101
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 100
Short-term adverse effects of anticancer drugs in patients with type 2 diabetes 100
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 99
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 98
New insights in thyroid cancer and p53 family proteins 96
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 96
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 95
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 95
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 95
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 94
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 93
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 93
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 92
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 90
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 90
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 90
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 89
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 88
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 88
BCR-ABL tyrosine kinase activity modulates survivin expression via PI3K/AKT 88
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 86
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 86
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 86
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 85
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 84
BCR-ABL tyrosine kinase activity modulates Survivin expression in CML cells 84
Opportunities and challenges of liquid biopsy in thyroid cancer 84
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 82
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 80
Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling 79
Possible role of the transcription factor interferon regulatory factor 1 (IRF-1) in the regulation of ornithine decarboxylase (ODC) gene expression during IFN gamma macrophage activation 78
SELECTIVE INHIHBITION OF LEUKEMIA CELL PROLIFERATION BY BCR-ABL ANTISENSE OLIGODEOXYNUCLEOTIDES SCIENCE 75
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 75
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 74
The PU.1 transcription factor induces cyclin D2 expression in U937 cells 74
Apoptosi mediata da Fas in cellule monocitiche umane 72
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 71
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 71
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 71
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 70
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 70
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 70
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 70
POSITIVE AUTOREGULATION OF C-MYB BINDING SITES IN THE 5’ FLANKING REGION OF THE HUMAN C-MYB GENE 69
Silencing of survivin induced by BCR-ABL/JAK2/STAT3 pathway kills CML cells and sensitizes IM-resistant clones to hydroxyurea 69
POSSIBLE ROLE OF THE TRANSCRIPTION FACTOR INTERFERON REGULATORY FACTOR 1 (IRF-1) IN THE REGULATION OF ORNITHINE DECARBOXYLASE (ODC) GENE EXPRESSION DURING IFN GAMMA MACROPHAGE ACTIVATION 69
Ruolo del transcription factor interferon regulatory factor 1 (IRF-1) nella regolazione dell’espressione del gene della ornitina decarbossilasi durante l’attivazione di macrofagi umani mediata da IFN-gamma 68
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 68
ROLE OF INTERFERON REGULATORY FACTOR-1 (IRF-1) IN MONOCYTE FAS EXPRESSION AND FAS-MEDIATED APOPTOSIS 66
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 65
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 65
Implications of antidepressants use in breast cancer: A brief review 65
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma 64
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 63
Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded 63
Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis 63
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 60
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 59
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 58
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 58
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 58
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 58
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides 58
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 58
ROLE OF INTERFERON REGULATORY FACTOR 1 IN MONOCYTE/MACROPHAGE DIFFERENTIATION 57
Role of Interferon Regulatory Factor-5 in Chronic Myeloid Leucemia 55
Role of NFkB in cytokine expression in normal Bone Marrow Cells 55
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 55
Computational and biological characterization of nuclear import/export signals of the human BCR protein 55
Ruolo funzionale dell’Interferon Regulatory Factor 1 (IRF-1) nell’attivazione di macrofagi umani mediata dal IFN 55
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 55
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 54
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 54
IRF5 promotes the proliferation of human thyroid cancer cells. 54
Long-acting insulin analogs and cancer 54
Role of Interferon Regulatory Factor-5 (IRF-5) in solid and haematological malignancies 53
Transcriptional control of apoptosis related genes in Acute Myeloid Leukemia (AML) cells 52
QUANTITATIVE ANALYSIS OF APOPTOTIS RELATED GENES IN CHRONIC MYELOGENOUS LEUKEMIA (CML) CELLS 52
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 52
Ruolo dell’NFkB nell’apoptosi in cellule leucemiche e normali 51
Silencing of survivin induced by BCR/ABL/JAK2/STAT3 pathway killes CML cells and sensitizes IM-resistant clones to hydroxyurea 50
Totale 8.145
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.727
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021502 0 0 0 12 142 18 55 4 129 14 91 37
2021/2022778 72 115 18 12 128 7 117 26 64 10 34 175
2022/20231.497 120 101 53 182 94 234 19 263 327 21 52 31
2023/2024791 65 106 36 36 34 190 7 59 5 27 157 69
2024/20252.977 47 456 127 147 609 390 178 83 191 244 309 196
2025/20261.612 338 287 827 160 0 0 0 0 0 0 0 0
Totale 8.968